Ibrx stock price forecast analysts monitoring global biotech

Analysts monitoring global biotech trends see the IBRX stock price forecast aligning with sector growth in Asia-Pacific markets, which could bolster share demand and sustain prices near $6. The investors in ImmunityBio, Inc. 's ( NASDAQ:IBRX ) will be rubbing their hands together with glee today, after the share price leapt 25% to US$2.51 in the week following its quarterly results. Revenues came in at US$17m, in line with expectations, while statutory losses per share were substantially higher than expected, at US$0.15 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on ImmunityBio after the latest results. CSX Stock Rally: Strong Options Flow, Analyst Price Targets The IBRX stock price forecast models remain sensitive to trial data cadence. Positive interim results in Q2 could act as a catalyst, pushing the stock into the $6.50–$7.00 valuation corridor.